Covid19 Clinical Trial - Use of Desferal for Prevention of ARDS in

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

Clinical Trial Description

COVID-19 is a condition caused by a coronavirus (called SARS-CoV-2) that was first identified in late 2019. In 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for COVID-19 has yet been developed. Recent theory showed that the severe respiratory manifestations could be due to iron toxicity which cause intense inflammation in the alveoli and hence the ground glass appearance that was seen in ragdiology imaging

Objective :

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

Randomisation:

Participants are randomly allocated to either standard care or standard care plus Desferal injection. Randomization will be done through computer generated list by principal investigator. Allocation will be determined by block randomisation, stratified by hospital. This will be carried out by an independent statistician, prior to the trial commencement, using Stata (StataCorp, College Station, TX, USA) to generate the allocation sequence. Allocations will be concealed within sequentially numbered, sealed opaque envelopes, prepared by two research assistants who are independent of the trial Blinding This study will be single blind. Doctors will not be blinded to intervention allocation due to lack of feasibility

Sample size:

Two hundred participants randomized into two groups each 100 individuals. The trial will begin as a 1:1 randomised trial Intervention Model Parallel assignment Desferal group An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours. The total amount administered should not exceed 6000 mg in 24 hours

Placebo group Will receive glucose 5% over 4 hrs infusion

Standard care :- including clexan 40, antibiotics, corticosteroids ( as anti-inflammatory agent) and hydroxychloroquine ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04389801
Study type	Interventional
Source	Cairo University
Contact
Status	Not yet recruiting
Phase	Phase 4
Start date	June 1, 2020
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04333732` - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION	Phase 3
Completed	`NCT04357457` - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia	Phase 3
Terminated	`NCT04435795` - Inhaled Ciclesonide for Outpatients With COVID19	Phase 2/Phase 3
Completed	`NCT04357444` - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19	Phase 2
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT05052320` - Audiological Assessment of Recovered Covid 19 Subjects.
Withdrawn	`NCT04426344` - Core Warming of COVID-19 Patients	N/A
Recruiting	`NCT05595031` - Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Terminated	`NCT04401410` - Anti-SARS Cov-2 T Cell Infusions for COVID 19	Phase 1
Completed	`NCT04445337` - Stellate Ganglion Blockade in COVID-19 Positive Patients	N/A
Active, not recruiting	`NCT04374487` - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications	Phase 2
Completed	`NCT04403243` - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19	Phase 2
Completed	`NCT04375644` - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed	`NCT04394078` - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting	`NCT04407923` - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Withdrawn	`NCT04519411` - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure	N/A
Completed	`NCT04426305` - Community Health Workers Against COVID19	N/A
Recruiting	`NCT04492514` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation	Phase 2
Completed	`NCT04399980` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms